Page last updated: 2024-08-23

1-deoxynojirimycin and Non-alcoholic Fatty Liver Disease

1-deoxynojirimycin has been researched along with Non-alcoholic Fatty Liver Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M1
Kishida, Y; Ohno, H; Oki, K; Okubo, H; Yoneda, M1
Hu, B; Hu, H; Jiang, N; Liu, H; Ma, J; Yang, H; Zhang, Z; Zheng, J; Zhu, L; Zou, X1
Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T1

Reviews

1 review(s) available for 1-deoxynojirimycin and Non-alcoholic Fatty Liver Disease

ArticleYear
Glycosphingolipids and insulin resistance.
    Advances in experimental medicine and biology, 2011, Volume: 721

    Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction

2011

Other Studies

3 other study(ies) available for 1-deoxynojirimycin and Non-alcoholic Fatty Liver Disease

ArticleYear
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
    Journal of pharmacological sciences, 2021, Volume: 147, Issue:2

    Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Gastrointestinal Absorption; Gene Expression; Glucose; Insulin Resistance; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Patient Acuity; RNA, Messenger; Sodium-Glucose Transporter 1; Sorbitol

2021
Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    Journal of gastroenterology, 2017, Volume: 52, Issue:11

    Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease

2017
1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis.
    The Journal of nutritional biochemistry, 2019, Volume: 71

    Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Glucose Intolerance; Hepatitis; Insulin; Lipids; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease

2019